Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single‐arm, phase 2 study
Authors: Harding James J. , Yang Tsai‐Sheng , Chen Yen‐Yang , Feng Yin‐Hsun , Yen Chia‐Jui , Ho Ching‐Liang , Huang Wen‐Tsung , El Dika Imane , Akce Mehmet , Tan Benjamin , Cohen Stacey A. , Meyer Timothy , Sarker Debashis , Lee Dae‐Won , Ryoo Baek‐Yeol , Lim Ho Yeong , Johnston Amanda , Bomalaski John S. , O’Reilly Eileen M. , Qin Shukui , Abou‐Alfa Ghassan K. 
Published: August 2021

BackgroundArginine starvation depletes the micronutrients required for DNA synthesis and interferes with both thymidylate synthetase activity and DNA repair pathways in preclinical models of hepatocellular carcinoma (HCC). Pegylated arginine deiminase (ADI‐PEG 20), an arginine degrader, potentiates the cytotoxic activity of platinum and pyrimidine antimetabolites in HCC cellular and murine models.MethodsThis was a global, multicenter, open‐label, single‐arm, phase 2 trial of ADI‐PEG 20 and modified 5‐fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) in patients who had HCC with Child‐Pugh A cirrhosis and disease progression on ≥2 prior lines of treatment. The primary objective was the objective response rate assessed according to Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary objectives were to estimate progression‐free survival, overall survival, safety, and tolerability. Eligible patients were treated with mFOLFOX6 intravenously biweekly at standard doses and ADI‐PEG‐20 intramuscularly weekly at 36 mg/m2.ResultsIn total, 140 patients with advanced HCC were enrolled. The median patient age was 62 years (range, 30‐85 years), 83% of patients were male, 76% were of Asian race, 56% had hepatitis B viremia, 10% had hepatitis C viremia, 100% had received ≥2 prior lines of systemic therapy, and 39% had received ≥3 prior lines of systemic therapy. The objective response rate was 9.3% (95% confidence interval [CI], 5.0%‐15.4%), with a median response duration of 10.2 months (95% CI, 5.8 months to not reached). The median progression‐free survival was 3.8 months (95% CI, 1.8‐6.3 months), and the median overall survival was 14.5 months (95% CI, 13.6‐20.9 months). The most common grade ≥3 treatment‐related events were neutropenia (32.9%), white blood cell count decrease (20%), platelet count decrease (19.3%), and anemia (9.3%).ConclusionsConcurrent mFOLFOX6 plus ADI‐PEG 20 exhibited limited antitumor activity in patients with treatment‐refractory HCC. The study was terminated early, and no further evaluation of the combination will be pursued.Lay Summary

Arginine is an important nutrient for hepatocellular carcinoma (HCC).

The depletion of arginine with pegylated arginine deiminase (ADI‐PEG 20), an arginine degrader, appeared to make chemotherapy (FOLFOX) work better in animal models of HCC and in patients with HCC on an early phase clinical trial.

To formally test this hypothesis in the clinical setting, a large, global, phase 2 clinical trial was conducted of ADI‐PEG 20 and FOLFOX in the treatment of patients with refractory HCC.

The study showed limited activity of ADI‐PEG 20 and FOLFOX in advanced HCC and was stopped early.